Teleflex Incorporated reports developments for a global medical technology business that supplies hospitals and healthcare providers with devices used in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Its established brands include Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck.
Recurring Teleflex news covers quarterly financial results, outlook updates, revenue trends by global product category, portfolio realignment and integration of acquired vascular intervention assets. Company updates also include governance and leadership changes, board committee matters, capital allocation actions, shareholder communications and operational initiatives such as integrated demand and supply planning.
Teleflex has announced a private offering of $500 million in senior notes due 2028, subject to market conditions. These notes will be guaranteed by its wholly-owned subsidiaries. The proceeds will be used to repay borrowings from its revolving credit facility. This offering is targeted at qualified institutional buyers and non-U.S. persons outside the U.S. and will not be registered under the Securities Act.
On May 18, 2020, Teleflex presented data at the AUA 2020 Virtual Experience highlighting the UroLift® System’s benefits for treating benign prostatic hyperplasia (BPH). Studies demonstrated that the minimally invasive treatment significantly preserves sexual function compared to traditional medical therapies. In a meta-analysis involving 1,039 men, UroLift patients reported substantial improvements in ejaculatory and erectile function over 48 months. Additionally, a real-world study found equivalent safety profiles across patient groups, with 84% of urinary retention patients becoming catheter-independent post-treatment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.